Corporate Insiders Point to Three Stocks Poised to Explode

Two different insiders at Five Below Inc. (NASDAQ:FIVE) reported acquiring stock last week. Chief Executive Officer and President Joel D. Anderson bought 5,000 shares for $33.53 each earlier this week, bolstering his overall holding to 21,113 shares. Moving on to the next insider, director David M. Mussafer, who has filed a Form 4 indicating that Sunley House Capital Master Limited Partnership, in which he holds a limited partnership interest, acquired 90,000 shares at a price of $33.35 per share. In addition to this indirect ownership stake, the director also owns 2,271 shares directly. Going back to the company itself, Deutsche Bank reduced the price target on Five Below earlier this month to $42 from $44, after the retailer released its latest earnings results (read more details). The stock has not managed to bounce back since then (shares have lost 16% since September 3), so it appears that the CEO is buying shares in the belief that they are undervalued. Jim Simons’ Renaissance Technologies, one of the top shareholders of Five Below Inc. (NASDAQ:FIVE), boosted its stake in the retailer to nearly 567,000 shares during the recent quarter.

Ultimately, Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)’s Chief Executive Officer, Dr. Seth Lederman, added 6,000 shares to the holding that now comprises 71,074 shares. The additional shares were purchased on Friday at $6.5 per unit. It is also worth mentioning that the CEO also owns a few hundred thousand shares indirectly. The stock performance of the clinical-stage pharmaceutical company has been quite volatile this year, but it still managed to deliver a year-to-date return of 6%. The company is currently working on three efficacy studies started during the first half of the year, so current and potential investors in the stock may be looking forward to see some results from these trials. To be more specific on what Tonix’s team is currently working on, these three studies involve next-generation medicines for tension headache, post-traumatic stress disorder, and fibromyalgia. James E. Flynn’s Deerfield Management reported owning 1.32 million shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) through its 13F for the April – June quarter.

Disclosure: None